Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same

• US 20050287638A1
• Filed: 05/12/2005
• Published: 12/29/2005
• Est. Priority Date: 04/25/2000
• Status: Abandoned Application

• Current Assignee: The Board of Regents of the University of Colorado (University of Colorado System)
• Original Assignee: The Board of Regents of the University of Colorado (University of Colorado System)
• Inventors: Weigel, Janet, Weigel, Paul H.
• Application Number:
  US11/128,059
• Publication Number:
  US 20050287638A1
• Time in Patent Office: Days
• US Class Current: 435/69.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748

Abstract

A purified recombinant mammalian HARE comprising a polypeptide which is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate is disclosed, as well as methods of expressing and using same. Also disclosed are functionally active variants of HARE which are able to specifically bind at least one of HA, chondroitin and chondroitin sulfate, as well as methods of expressing and using same.

Claims

1. A purified recombinant mammalian HARE comprising a polypeptide which is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate, the purified recombinant mammalian HARE comprising at least one of items (a) through (f):

wherein item (a) comprises a purified recombinant mammalian HARE having a molecular weight of about 190 kDa;

wherein item (b) comprises a purified recombinant mammalian HARE having a molecular weight of about 315 kDa;

wherein item (c) comprises a purified recombinant mammalian HARE having an amino acid sequence in accordance with SEQ ID NO;

4;

wherein item (d) comprises a purified recombinant mammalian HARE having an amino acid sequence in accordance with SEQ ID NO;

96;

wherein item (e) comprises a purified recombinant human HARE; and

wherein item (f) comprises a purified recombinant mammalian HARE which is recognized by at least one of the monoclonal antibodies mAb-30, mAb-154, mAb-159 and a monoclonal antibody which demonstrates an immunological binding characteristic of such monoclonal antibodies.

2. A method of producing a recombinant, functionally active mammalian HARE wherein the recombinant, functionally active HARE is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate, the method comprising the steps of:

providing a recombinant host cell containing a recombinant DNA segment which encodes and is capable of expressing the recombinant mammalian HARE of claim 1;

and

culturing the recombinant host cell under conditions that allow for expression of the recombinant DNA segment encoding the functionally active, recombinant mammalian HARE, thereby producing recombinant, functionally active mammalian HARE which is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate.

3. The method of claim 2 further comprising the step of separating and purifying the recombinant, functionally active mammalian HARE from the recombinant host cell.

4. An isolated nucleic acid sequence encoding a functionally active mammalian HARE which is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate, the isolated nucleic acid sequence comprising a nucleic acid sequence in accordance with SEQ ID NO:

95.

5. A recombinant vector selected from the group consisting of a plasmid, cosmid, phage, and virus vector and wherein the recombinant vector further comprises the isolated nucleic acid sequence encoding a functionally active mammalian HARE of claim 4.

6. The recombinant vector of claim 5, wherein the recombinant vector is further defined as an expression vector.

7. The recombinant vector of claim 6, wherein the expression vector comprises a promoter operatively linked to the coding region of the mammalian HARE.

8. A recombinant host cell comprising the recombinant vector of claim 5.

9. The recombinant host cell of claim 8, wherein the host cell is further defined as a eucaryotic cell.

10. The recombinant host cell of claim 8, wherein the recombinant host cell produces a functionally active mammalian HARE which specifically binds and endocytoses at least one of HA, chondroitin and chondroitin sulfate.

11. The recombinant host cell of claim 8, wherein the recombinant vector is introduced into the host cell by a method selected from the group consisting of transfection, electroporation, transduction and combinations thereof.

12. The recombinant host cell of claim 8, wherein the purified nucleic acid sequence is integrated into a chromosome of the recombinant host cell.

13. A method of producing a functionally active mammalian HARE which is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate, the method comprising the steps of:

providing the recombinant host cell of claim 8, wherein the recombinant host cell is capable of expressing a functionally active mammalian HARE; and

culturing the recombinant host cell under conditions that allow for expression of the purified nucleic acid sequence encoding a functionally active mammalian HARE, thereby producing a functionally active mammalian HARE which is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate.

14. The method of claim 13 further comprising the step of separating and purifying the functionally active mammalian HARE from the recombinant host cell.

15. An isolated nucleic acid sequence encoding a functionally active variant or fragment of HARE, wherein the functionally active variant or fragment of HARE is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate, the nucleic acid sequence comprising at least one of items (a) through (p):

wherein item (a) comprises a nucleic acid sequence in accordance with SEQ ID NO;

55;

wherein item (b) comprises a nucleic acid sequence in accordance with SEQ ID NO;

57;

wherein item (c) comprises a nucleic acid sequence in accordance with SEQ ID NO;

59;

wherein item (d) comprises a nucleic acid sequence in accordance with SEQ ID NO;

61;

wherein item (e) comprises a nucleic acid sequence in accordance with SEQ ID NO;

73;

wherein item (f) comprises a nucleic acid sequence in accordance with SEQ ID NO;

75;

wherein item (g) comprises a nucleic acid sequence in accordance with SEQ ID NO;

77;

wherein item (h) comprises a nucleic acid sequence in accordance with SEQ ID NO;

79;

wherein item (i) comprises a nucleic acid sequence in accordance with SEQ ID NO;

81;

wherein item (j) comprises a nucleic acid sequence which will hybridize to a complement of at least one of the nucleic acid sequences of items (a)-(i) or a fragment of at least one of the nucleic acid sequences defined in items (a)-(i) under stringent hybridization conditions;

wherein item (k) comprises a nucleic acid sequence that has at least about 76% sequence identity to at least one of the nucleic acid sequences defined in items (a)-(i);

wherein item (l) comprises a nucleic acid sequence that has at least about 80% sequence identity to at least one of the nucleic acid sequences defined in items (a)-(i);

wherein item (m) comprises a nucleic acid sequence that has at least about 85% sequence identity to at least one of the nucleic acid sequences defined in items (a)-(i);

wherein item (n) comprises a nucleic acid sequence that has at least about 90% sequence identity to at least one of the nucleic acid sequences defined in items (a)-(i);

wherein item (o) comprises a nucleic acid sequence that encodes semiconservative or conservative amino acid changes when compared to at least one of the nucleic acid sequences defined in items (a)-(i); and

wherein item (p) comprises a nucleic acid sequence which but for the degeneracy of the genetic code, or encoding of functionally equivalent amino acids, would hybridize to at least one of the nucleic acid sequences defined in items (a)-(i).

16. The isolated nucleic acid sequence of claim 15, wherein the functionally active variant or fragment of HARE encoded by the isolated nucleic acid sequence is soluble.

17. A recombinant vector selected from the group consisting of a plasmid, cosmid, phage, and virus vector and wherein the recombinant vector further comprises the purified nucleic acid sequence encoding a functionally active variant or fragment of HARE of claim 15.

18. The recombinant vector of claim 17, wherein the recombinant vector is further defined as an expression vector.

19. The recombinant vector of claim 17, wherein the expression vector comprises a promoter operatively linked to the coding region of the HARE variant or fragment.

20. The recombinant vector of claim 17, wherein the functionally active variant or fragment of HARE encoded by the purified nucleic acid sequence is soluble.

21. A recombinant host cell comprising the recombinant vector of claim 17.

22. The recombinant host cell of claim 21, wherein the host cell is further defined as a eucaryotic cell.

23. The recombinant host cell of claim 21, wherein the recombinant host cell produces a functionally active variant or fragment of HARE which specifically binds and endocytoses at least one of HA, chondroitin and chondroitin sulfate.

24. The recombinant host cell of claim 21, wherein the recombinant vector is introduced into the host cell by a method selected from the group consisting of transfection, electroporation, transduction and combinations thereof.

25. The recombinant host cell of claim 21, wherein the purified nucleic acid sequence is integrated into a chromosome of the recombinant host cell.

26. The recombinant host cell of claim 21, wherein the functionally active variant or fragment of HARE encoded by the purified nucleic acid sequence is soluble.

27. A method of producing a functionally active variant or fragment of HARE wherein the functionally active variant or fragment of HARE is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate, the method comprising the steps of:

providing the recombinant host cell of claim 21, wherein the recombinant host cell is capable of expressing a functionally active variant or fragment of HARE; and

culturing the recombinant host cell under conditions that allow for expression of the purified nucleic acid sequence encoding a functionally active variant or fragment of HARE, thereby producing a functionally active variant or fragment of HARE which is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate.

28. The method of claim 27 further comprising the step of separating and purifying the functionally active variant or fragment of HARE from the recombinant host cell.

29. The method of claim 27, wherein the functionally active variant or fragment of HARE is soluble.

30. The method of claim 29 further comprising the step of separating and purifying the functionally active soluble variant or fragment of HARE from the recombinant host cell.

31. A purified recombinant mammalian HARE variant or fragment comprising a polypeptide which is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate, the purified recombinant mammalian HARE variant or fragment comprising at least one of items (a) through (p):

wherein item (a) comprises a soluble fragment of HARE;

wherein item (b) comprises an amino acid sequence in accordance with SEQ ID NO;

56;

wherein item (c) comprises an amino acid sequence in accordance with SEQ ID NO;

58;

wherein item (d) comprises an amino acid sequence in accordance with SEQ ID NO;

60;

wherein item (e) comprises an amino acid sequence in accordance with SEQ ID NO;

62;

wherein item (f) comprises an amino acid sequence in accordance with SEQ ID NO;

74;

wherein item (g) comprises an amino acid sequence in accordance with SEQ ID NO;

76;

wherein item (h) comprises an amino acid sequence in accordance with SEQ ID NO;

78;

wherein item (i) comprises an amino acid sequence in accordance with SEQ ID NO;

80;

wherein item (j) comprises an amino acid sequence in accordance with SEQ ID NO;

82;

wherein item (k) comprises an amino acid sequence encoded by a nucleic acid sequence which will hybridize to a complement of a nucleic acid sequence that encodes at least one of the amino acid sequences of items (b)-(j) or a fragment of a nucleic acid sequence that encodes at least one of the amino acid sequences defined in items (b)-(j) under stringent hybridization conditions;

wherein item (l) comprises an amino acid sequence that has at least about 76% sequence identity to at least one of the amino acid sequences defined in items (b)-(j);

wherein item (m) comprises an amino acid sequence that has at least about 80% sequence identity to at least one of the amino acid sequences defined in items (b)-(j);

wherein item (n) comprises an amino acid sequence that has at least about 85% sequence identity to at least one of the amino acid sequences defined in items (b)-(j);

wherein item (o) comprises an amino acid sequence that has at least about 90% sequence identity to at least one of the amino acid sequences defined in items (b)-(j); and

wherein item (p) comprises an amino acid sequence that has semiconservative or conservative amino acid changes when compared to at least one of the amino acid sequences defined in items (b)-(j).

32. A method of producing a functionally active HARE variant or fragment wherein the functionally active HARE variant or fragment is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate, the method comprising the steps of:

providing a recombinant host cell containing a recombinant DNA segment which encodes and is capable of expressing the recombinant mammalian HARE variant or fragment of claim 31;

and

culturing the recombinant host cell under conditions that allow for expression of the recombinant DNA segment encoding a recombinant mammalian HARE variant or fragment, thereby producing a recombinant, functionally active mammalian HARE variant or fragment which is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate.

33. The method of claim 32 further comprising the step of separating and purifying the recombinant, functionally active, soluble mammalian HARE variant or fragment from the recombinant host cell.

34. A method of producing a recombinant, functionally active soluble HARE variant or fragment wherein the recombinant, functionally active soluble HARE variant or fragment is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate, the method comprising the steps of:

providing a recombinant host cell containing a recombinant DNA segment which encodes and is capable of expressing a recombinant, functionally active soluble HARE variant or fragment; and

culturing the recombinant host cell under conditions that allow for expression of the recombinant DNA segment encoding a recombinant, functionally active soluble HARE variant or fragment, thereby producing a recombinant, functionally active soluble HARE variant or fragment which is able to specifically bind at least one of HA, chondroitin and chondroitin sulfate.

35. The method of claim 34 further comprising the step of separating and purifying the recombinant, functionally active, soluble HARE variant or fragment from the recombinant host cell.

36. A method of preventing interaction between a first cell expressing HARE on a surface thereof and a second cell whose surface contains at least one of HA, chondroitin and chondroitin sulfate, the method comprising the steps of:

providing a functionally active, soluble variant or fragment of HARE capable of binding at least one of HA, chondroitin and chondroitin sulfate on the surface of the second cell; and

administering an effective amount of the functionally active, soluble variant or fragment of HARE, wherein the functionally active, soluble variant or fragment of HARE inhibits binding of HARE expressed on the surface of the first cell to at least one of HA, chondroitin and chondroitin sulfate on the surface of the second cell.

37. A kit for determining the presence of at least one of HA, heparin, CS-A, CS-B, CS-C, CS-D, CS-E, chondroitin, keratan sulfate, and heparan sulfate, comprising:

at least one variant or fragment of HARE, wherein the at least one variant or fragment of HARE is capable of selectively binding at least one of HA, heparin, CS-A, CS-B, CS-C, CS-D, CS-E, chondroitin, keratan sulfate, and heparan sulfate.

38. The kit of claim 37 wherein the at least one variant or fragment of HARE does not bind at least one of HA, heparin, CS-A, CS-B, CS-C, CS-D, CS-E, chondroitin, keratan sulfate, and heparan sulfate.

39. The kit of claim 37 further comprising a second variant of fragment of HARE, wherein the second variant or fragment of HARE is capable of binding at least one of heparin, CS-A, CS-B, CS-C, CS-D, CS-E, chondroitin, keratan sulfate, and heparan sulfate.

40. The kit of claim 39 wherein the second variant or fragment of HARE does not bind at least one of heparin, CS-A, CS-B, CS-C, CS-D, CS-E, chondroitin, keratan sulfate, and heparan sulfate, and wherein the two variants'"'"' inability to bind at least one of heparin, CS-A, CS-B, CS-C, CS-D, CS-E, chondroitin, keratan sulfate, and heparan sulfate is different.